Clinical Trial Update: Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 1/2 study of the combination of vorinostat and azacitidine in patients with myelodysplastic syndromes and various sub…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
• Anemia
• Erythroid Leukemia
• Megakaryoblastic Leukemia
• Myelodysplastic Syndrome
• Myelodysplastic Syndrome with Excess Blasts
• Myelodysplastic Syndrome with Ring Sideroblasts
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING